You need fewer quick “boosts” to your immunity and more long-term healthy habits, including maintaining strong relationships ...

The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.

Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of ...

The statements regarding Herpafend have not been evaluated by the Food and Drug Administration (FDA). This product is not ...

Background:Respiratory viruses, including influenza viruses, respiratory syncytial virus (RSV), coronaviruses, and other emerging zoonotic pathogens, remain ...

Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in ...

Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq complianceSOUTH SAN FRANCISCO, Calif., Oct.

A study published in Nature looks at COVID-19 mRNA vaccines and the immune response to tumours during immunotherapy. Prof Andrew Beggs, MRC Senior Clinical Fellow and Consultant Colorectal Surgeon, ...

STAT Wunderkind Sydney Ramirez is revealing the immune system in our nasal passages and working toward better disease ...

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a ...

Oncologi, Inc., a biotechnology company developing next-generation RNA-based cancer immunotherapies, today announced that the ...

The poster for INSIGHT-003 and the Trial in Progress ePoster for TACTI-004 can be found at the Posters & Publications section of Immutep’s website.